Tilray Medical has launched pastilles into the Australian market for the first time.
Three medicines, each in packs of 60, will be available through the Special Access Scheme with doctors provided with a THC, balanced and CBD option.
Tilray chief strategy officer and head of international, Denise Faltischek, described the launch in Australia as a “milestone” for the company.
“Our dedication to innovation and patient care drives us to continuously expand our medical cannabis portfolio, ensuring patients receive the best possible treatment options tailored to meet their needs and preferences,” she said.
Pastilles have become a popular dosage form among prescribers and patients in recent months. In March, they represented 17% of successful SAS-B applications, up from 14% in both January and February.
InhaleRx progresses panic disorder trial
InhaleRx has executed a study order with contract research organisation Ingenu to oversee a phase 1 clinical trial for drug candidate IRX-616a.
The randomised, double blind, placebo-controlled study will explore the efficacy, safety and tolerability of the inhaled drug for the treatment of panic disorder.
IRX chief executive Darryl Davies said: “The execution of this study order allows for trial drug manufacturing timelines to be secured, and for progression of our planning for the commencement of phase 2 trial dosing of healthy subjects later in the year.
“There are currently no FDA approved, rapid onset, inhaled therapies available to panic disorder patients. IRX-616a represents an exciting opportunity to address this very important unmet need.”
The ASX-listed company is also preparing for a phase 2 trial of its IRX-211 drug for the treatment of breakthrough cancer pain.
NSW government seeks feedback on hemp plan
The NSW government is seeking feedback on its draft NSW Hemp Industry Development Plan following work by a taskforce to identify barriers and opportunities for the local industry.
The draft plan outlines where government, industry and stakeholders can collaborate to support the growth of the hemp sector in the state. It includes an industry vision statement, four development objectives to provide strategic direction and actions for sector development.
Submissions close on May 19 with the government aiming to finalise the plan by the middle of the year.
BS3 makes key hire
Pharmaceuticals and therapeutic goods storage and logistics specialist BS3 has appointed former Canopy Growth and LeafCann staffer Michelle Johnson as its new general manager.
Johnson’s expertise spans GMP facility design and operations management, lean manufacturing, auditing, corrective and preventive action, quality control, qualification, validation, HR management, and business process improvement.
She has held operational leadership roles at Canopy Growth Australia, LeafCann, Baxter Healthcare, Lifeblood, Donor Tissue Bank of Victoria and Mayne Pharma.
BS3 managing director Andrew Gibson said: “Michelle’s comprehensive experience and strong leadership qualities will be instrumental as BS3 continues to grow and deliver innovative cold chain solutions to our clients.”
